Heart Rate Reduction in Heart Failure

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with heart failure (HF) have a limited exercise tolerance,few pharmacological interventions have been proven effective in improving exercise capacity. At the presence there i conflicting evidence on the effectiveness of beta-blockers on exercise capacity. Ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left ventricular dysfunction and heart rate > 70 bpm. The association of ivabradine and atenolol has been proven effective in increasing exercise tolerance in patients with ischemic heart disease. Aim of the present study is to evaluate the effect of heart rate reduction with ivabradine, carvedilol or their combination in patients with heart failure of ischemic origin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IRCCS San Raffaele
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• heart failure II-III

• ischemic origin

• stable medications from at least 3 months

• > 3 months from an acute ischemic syndrome or revascularization procedure

• naive on heart rate reducing agents

Exclusion Criteria:

• bradycardia

• hypersensitivity or contraindications to study drugs

• exercise tolerance at 6 minute walking test <100 m or >400 m